These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2684694)

  • 1. [A multicenter clinical trial of SMS 201-995 (octreotide acetate) in acromegaly and gigantism].
    Shimatsu A; Imura H; Irie M; Nakagawa S; Goto Y; Shimizu N; Takeda R; Kato Y; Saito S; Ibayashi H
    Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):640-52. PubMed ID: 2684694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term treatment of acromegaly and gigantism with octreotide (SMS 201-995)].
    Shimatsu A; Imura H; Irie M; Nakagawa S; Goto Y; Shimizu N; Takeda R; Kato Y; Saito S; Ibayashi H
    Nihon Naibunpi Gakkai Zasshi; 1992 Feb; 68(2):89-99. PubMed ID: 1592144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly.
    Wang C; Lam KS; Arceo E; Chan FL
    J Clin Endocrinol Metab; 1989 Sep; 69(3):670-7. PubMed ID: 2668325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
    Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
    J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
    Lamberts SW; Uitterlinden P; del Pozo E
    J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
    Shi YF; Harris AG; Zhu XF; Deng JY
    Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
    Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
    J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly.
    Stewart PM; Kane KF; Stewart SE; Lancranjan I; Sheppard MC
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3267-72. PubMed ID: 7593436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
    Ezzat S; Redelmeier DA; Gnehm M; Harris AG
    J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study.
    Tahara S; Murakami M; Kaneko T; Shimatsu A
    Endocr J; 2017 Jul; 64(7):735-747. PubMed ID: 28592706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
    Riedel M; Günther T; von zur Mühlen A; Brabant G
    Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).
    Barnard LB; Grantham WG; Lamberton P; O'Dorisio TM; Jackson IM
    Ann Intern Med; 1986 Dec; 105(6):856-61. PubMed ID: 2877605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and long-term effects of SMS 201-995 in acromegaly.
    Lamberts SW; del Pozo E
    Scand J Gastroenterol Suppl; 1986; 119():141-8. PubMed ID: 2876498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.